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Letters to the Editorof patients who died in the first 2 days
postoperatively.
Second, confounding by contrain-
dication could have been introduced
from patients experiencing significant
bleeding events (thus prohibiting clo-
pidogrel use) who would be more
likely to be in the aspirin monotherapy
cohort and with greater risks of major
outcomes. Unfortunately, data regard-
ing reasons behind withholding
clopidogrel were not included and it
appears that surrogates of intraopera-
tive bleeding including transfusion re-
quirements and postoperative chest
tube outputs were unmeasured.
Finally, selection bias may also have
been introduced with the exclusion of
patients who were administered late
postoperative clopidogrel (>postoper-
ative day 2), patients who necessarily
survived at least the first 3 days. It is un-
clear whether such exclusions affected
the reported rates of in-hospital mortal-
ity for on-pump CABGs (1.5%) in this
study, which are half the rates reported
in the Society of Thoracic Surgeons
(STS) national database (3.05%).4
The nonrandomized study of phar-
macologic treatment effects presents
major methodologic challenges, in-
cluding using current STS definitions
of operative outcomes in surgical se-
ries. Postdischarge surveillance has
recently been suggested to replace
current 30-day mortality benchmark.5
Given the rapidly changing nature of
patient status in the postoperative
period, it is imperative that timing of
exposure and outcome assessment be
accurate. It would be informative for
the authors to treat clopidogrel expo-
sure in a time-dependent fashion to
more accurately dissect the role of
dual antiplatelet therapy after CABG.
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Vaduganathan and Suissa raised 3
major concerns regarding our recent
article.1 We do not think immortal
time bias was present in our study,
but we agree with the possibility of
confounding by contraindication and
selection bias. Although analyzing
clopidogrel treatment as a time-
varying exposure can be useful, it
does not resolve the fundamental issue
that arises from the lack of informa-
tion on the timing of the events.
Thus, the causal effect of clopidogrel
on ischemic and bleeding events
would remain unidentified.
Their first concern was the possibil-
ity of immortal time bias if patients
needed to have survived 2 days after
surgery to be counted in the clopidog-
rel group. What we did not describe
clearly in our article was that survival
for at least 2 days after surgery was an
eligibility criterion for all patients, ir-
respective of whether they received
clopidogrel or not, since we believed
that death in the first 24 to 48 hours af-
ter the operation would probably beof Thoracic and Cardiovascular Surgerelated to direct surgical complica-
tions rather than to subsequent aspirin
or clopidogrel treatment. Therefore,
we think that immortal time bias
does not apply to our work.
A second concern was confounding
by contraindication (or indication) if,
for example, physicians were more
likely to prescribe clopidogrel to pa-
tients who were at a high risk of peri-
operative ischemic events and less
likely to prescribe clopidogrel to those
who were at a high risk of bleeding
events. This is a common problem
with observational pharmacoepide-
miologic studies, and we attempted
to control for it by using propensity
score analysis.2 Nonetheless, we rec-
ognized it as a possibility in our own
work (‘‘it is possible that unmeasured
factors might have influenced sur-
geons to prescribe clopidogrel to pa-
tients with lower perceived risk of
bleeding,’’ p. 1382). As we discussed
in our article, unavailability of de-
tailed clinical data in the University
HealthSystem Consortium database
(‘‘.transfusion requirement prior to
or during operation, procedural char-
acteristics, and postoperative chest
tube output,’’ p. 1382) was a major
limitation that prevented us from
drawing any conclusive statement on
whether the reduction of in-hospital
mortality resulted from lower ische-
mic events or from lower bleeding
events.
The third concern was the possibil-
ity of selection bias resulting owing to
exclusion of patients who received
clopidogrel more than 2 days after sur-
gery. The scientific question that we
were interested in was to compare
the outcomes between early postoper-
ative clopidogrel use versus aspirin-
only treatment. We excluded patients
who received clopidogrel after 2
days because clopidogrel might have
been administered as a result of an is-
chemic event. If, in fact, these patients
were to be included in the analysis,
they should be considered as a down-
stream consequence of aspirin-only
treatment (not clopidogrel). Suchry c Volume 141, Number 3 851
Letters to the Editoranalyses would make early postopera-
tive clopidogrel use look more protec-
tive (and this is more likely for
ischemic events than for mortality,
eg, the reported odds ratio of 0.99
may be biased toward the null, see Ta-
ble 3). On the other hand, events might
have occurred after and owing to later
clopidogrel administration, in which
case they should not be counted as
a consequence of aspirin-only treat-
ment. A post hoc analysis is compati-
ble with either possibility, because
patients who received late postopera-
tive clopidogrel had a slightly higher
mortality (1.2%), higher ischemic
events (3.7%), and higher bleeding
events (7.9%) than those who re-
ceived early postoperative clopidog-
rel. Unfortunately, the lack of
information on the timing of each
event prevented us from differentiat-
ing between the 2 possibilities and
forced us to exclude patients with later
clopidogrel use altogether. On this
point, we fully agree with Vadugana-
than and Suissa that the accurate as-
sessment of the timing of exposure
and outcome is crucial in pharmacoe-
pidemiology research. In addition,852 The Journal of Thoracic and Cconsidering that ischemic and bleed-
ing events could be time-dependent
confounders affected by prior expo-
sure, if the timing of events were
available, the causal effect of early
clopidogrel treatment on in-hospital
mortality could be identified by apply-
ing G-computation methods.3,4
With regard to the discrepancy in in-
hospital mortality between our study
sample and the national Society of
Thoracic Surgeons (STS) database,5
this wasmainly driven by our selection
of study sample, not by excluding pa-
tients who received late postoperative
clopidogrel.We excluded high-risk pa-
tients who received preoperative clopi-
dogrel, were treated with warfarin, or
did not receive any antiplatelet treat-
ment at all. In addition, we used in-
hospital mortality, whereas the STS
database used a more comprehensive
30-day mortality.
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